S.03.02 Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy

Bakish, David; Hooper, Cynthia; Thornton, Marianne; Wiens, Andrew; Miller, Carlos O.; Thibaudeau, C.

doi:10.1016/s0924-977x(97)88363-0

Cited by 15 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of open label studies have reported a reduction in the latency of therapeutic response and antidepressant augmentation in treatment resistant patients following the co-administration of pindolol with SSRIs (Artigas et al, 1994;Blier and Bergeron, 1995;Bakish et al, 1997). Two of the earliest of these studies found that the concurrent administration of pindolol (7.5 mg t.i.d.)…”

Section: Introductionmentioning

confidence: 97%

Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression

Segrave

Nathan

2005

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

Co-administration of pindolol with SSRIs in patients with depression has been suggested as a way to both hasten and augment antidepressant response. Clinical trials have examined the efficacy of this treatment regime and conflicting results have been reported. The present review briefly presents the results of placebo-controlled double-blind trials of pindolol augmentation of SSRIs in patients with major depression, and focuses on factors that may account for the variability of findings. Additionally, a profile of the subset of patients who may most benefit from pindolol augmentation is outlined. Methodological factors such as qualitative differences in definitions of antidepressant response, the timing of pindolol administration and heterogeneous clinical characteristics of patient samples may contribute to the variability in the results of clinical trials to date. Similarly, individual differences in neuropathology, neurophysiology and genotype may also account for some of the inconsistencies in the findings. Finally, the results of recent neuroimaging studies suggest that the 2.5 mg t.i.d. dose of pindolol that has been used in all but one of these investigations may be suboptimal for achieving reliable and significant occupancy of 5-HT1A autoreceptors and may explain the contradictory nature of the results of investigations of pindolol augmentation.

show abstract

Section: Introductionmentioning

confidence: 97%

Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression

Segrave

Nathan

2005

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

show abstract

“…Pindolol is a ␤ -adrenergic receptor antagonist with affinity for the 5-HT 1A receptor (Hoyer and Schoeffter 1991). Initial open label clinical studies reported that the co-administration of pindolol with SSRI enhanced and/or accelerated the antidepressant effects of the SSRIs (Artigas et al 1994;Blier and Bergeron 1995;Bakish et al 1997). However, the results of subsequent double-blind controlled trials have been less consistent (Maes et al 1996(Maes et al , 1999Berman et al 1997Berman et al , 1999Perez et al 1997Perez et al , 1999Tome et al 1997;Zanardi et al 1997Zanardi et al , 1998Bordet et al 1998).…”

mentioning

confidence: 99%

Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans

Martínez

Hwang

Mawlawi

et al. 2001

Neuropsychopharmacology

114

View full text Add to dashboard Cite

Augmentation of selective serotonin reuptake inhibitors (SSRIs) therapy by the 5-HTThe antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs) is thought to be mediated by enhanced serotonin (5-HT) transmission. However, initial exposure to SSRIs is associated with no change or even a decrease in extracellular 5-HT levels in the terminal fields of the forebrain (Chaput et al. 1986;Invernizzi et al. 1992;

show abstract

“…In keeping with this hypothesis, selective (eg WAY 100635) and nonselective 5-HT 1A receptor antagonists have been shown to potentiate the increase in 5-HT ext produced by antidepressant drugs in the rat brain (see Artigas et al, 1996 for review). At the clinical level, several open-label Blier and Bergeron, 1995;Bakish et al, 1997) and placebo-controlled trials (Maes et al, 1996;Pérez et al, 1997;Tomé et al, 1997;Zanardi et al, 1997Zanardi et al, , 1998Bordet et al, 1998;Maes et al, 1999) have shown a faster action and/or greater efficacy of SSRIs when given in combination with the nonselective 5-HT 1A receptor antagonist pindolol. However, the efficacy of pindolol in chronically ill or treatment-resistant patients is questionable (Moreno et al, 1997;Tomé et al, 1997;Berman et al, 1999;Pérez et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Modulation of Serotonergic Function in Rat Brain by VN2222, a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist

Romero

Celada

Martı́n-Ruiz

et al. 2002

Neuropsychopharmacol

View full text Add to dashboard Cite

VN2222(1-(benzo [b]thiophen-3-yl)-3-[4-(2-methoxiphenyl piperazin-1-yl]propan-1-ol) is a potential antidepressant with high affinity for the serotonin transporter and 5-HT 1A receptors. Locally applied, VN2222 enhanced the extracellular 5-hydroxytryptamine (5-HT) concentration (5-HT ext ) in rat striatum to 780% of baseline whereas its systemic administration (1-10 mg/kg s.c.) reduced 5-HT ext . In the presence of citalopram, 8-OH-DPAT or VN2222 applied in medial prefrontal cortex reduced 5-HT ext . Fluoxetine, VN2222, and 8-OH-DPAT suppressed the firing rate of dorsal raphe 5-HT neurons (ED 50 : 790, 14.9, and 0.8 mg/kg i.v., respectively). These effects were antagonized by WAY 100635. Administration of VN2222 for 2 weeks desensitized 5-HT 1A receptors as assessed by microdialysis and single-unit recordings (ED 50 values for 8-OH-DPAT were 0.45 and 2.34 mg/kg i.v. for controls and rats treated with 6 mg/kg day VN2222). These results show that VN2222 is a mixed 5-HT reuptake inhibitor/5-HT 1A agonist that markedly desensitizes 5-HT 1A autoreceptors. These properties suggest that it may be a clinically effective dual action antidepressant drug.

show abstract

S.03.02 Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy

Cited by 15 publications

References 0 publications

Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression

Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression

Differential Occupancy of Somatodendritic and Postsynaptic 5HT1A Receptors by Pindolol A Dose-Occupancy Study with [11C]WAY 100635 and Positron Emission Tomography in Humans

Modulation of Serotonergic Function in Rat Brain by VN2222, a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist

Contact Info

Product

Resources

About